Genetic changes in stage pT2N0 prostate cancer studied by comparative genomic hybridization

被引:22
作者
Wolter, H
Gottfried, HW
Mattfeldt, T [1 ]
机构
[1] Univ Ulm, Dept Pathol, D-89069 Ulm, Germany
[2] Univ Ulm, Dept Urol, D-89069 Ulm, Germany
关键词
comparative genomic hybridization; stage pT2N0 prostate cancer; tumour suppressor genes; oncogenes;
D O I
10.1046/j.1464-4096.2001.01722.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To identify chromosomal regions important for progression in clinically organ-confined prostate cancer, as the genetic changes underlying the development and progression of prostate cancer are poorly understood. Materials and methods Comparative genomic hybridization (CGH) was used to search for DNA sequence copy-number changes in a series of 50 primary organ-confined prostate adenocarcinomas (pT2N0) removed by radical prostatectomy. Results CGH analysis indicated that 23 (46%) of the primary prostate adenocarcinomas showed chromosome alterations. The percentage of tumours with losses (38%) was higher than with gains (28%). Losses of 13q (24%), 8p (18%), 6q (10%), 16q (8%), 18q (6%) and 5q (6%) and gains of 17q (12%), 20q (12%), 9q (10%), 17p (8%) and Sq (6%) were the most frequent alterations. Amplifications were found at 8q24-qter. Minimal overlapping regions of loss, indicative of the presence of tumour-suppressor genes, were mapped to 13q21.1-q21.3 and 8p21.2, and minimal overlapping regions of gain, indicative of the presence of oncogenes, were found at 9q34.4-qter, 17q25-qter and 20q13.3-qter. There was a significant association between Gleason score and losses and gains (P=0.003), and an association between chromosomal imbalance and high histological grade (P=0.008). Conclusion Those results suggest that losses or gains of DNA in these regions are important for prostate cancer progression, and document the spectrum of chromosomal alterations in stage pT2N0 of clinically organ-confined prostate cancer.
引用
收藏
页码:310 / 316
页数:7
相关论文
共 37 条
  • [1] Identification of genetic markers for prostatic cancer progression
    Alers, JC
    Rochat, J
    Krijtenburg, PJ
    Hop, WCJ
    Kranse, R
    Rosenberg, C
    Tanke, HJ
    Schröder, FH
    van Dekken, H
    [J]. LABORATORY INVESTIGATION, 2000, 80 (06) : 931 - 942
  • [2] Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies -: Early cancers may contain aggressive genetic features
    Alers, JC
    Krijtenburg, PJ
    Vis, AN
    Hoedemaeker, RF
    Wildhagen, MF
    Hop, WCJ
    van der Kwast, TH
    Schröder, FH
    Tanke, HJ
    van Dekken, H
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (02) : 399 - 406
  • [3] [Anonymous], UROLOGIC PATHOLOGY
  • [4] Barth TFE, 2000, GENE CHROMOSOME CANC, V28, P353, DOI 10.1002/1098-2264(200007)28:3<353::AID-GCC15>3.0.CO
  • [5] 2-0
  • [6] Bentz M, 2000, GENE CHROMOSOME CANC, V27, P285, DOI 10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.3.CO
  • [7] 2-D
  • [8] Tumour-suppressor genes in prostatic oncogenesis: A positional approach
    Bookstein, R
    Bova, GS
    MacGrogan, D
    Levy, A
    Isaacs, WB
    [J]. BRITISH JOURNAL OF UROLOGY, 1997, 79 : 28 - 36
  • [9] Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO
  • [10] 2-L